Luis Ferran
- Clinical Biochemistry top 0.2%
- Advanced Glycation End Products research 3
-
- Natural Antidiabetic Agents Studies 1
- Diabetes, Cardiovascular Risks, and Lipoproteins 1
- Nephrology top 5%
- Rheumatology top 5%
- Immunology top 10%
- T-cell and B-cell Immunology 1
- Immunotherapy and Immune Responses 1
-
- RNA Interference and Gene Delivery 1
- S100 Proteins and Annexins 1
-
- Alzheimer's disease research and treatments 1
Luis Ferran
5 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Clinical Biochemistry 1.1k
- Endocrinology, Diabetes and Metabolism 556
- Nephrology 203
- Rheumatology 317
- Immunology 305
Countries citing papers authored by Luis Ferran
This map shows the geographic impact of Luis Ferran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Ferran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Ferran more than expected).
Fields of papers citing papers by Luis Ferran
This network shows the impact of papers produced by Luis Ferran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Ferran. The network helps show where Luis Ferran may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Luis Ferran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 52 | |
| 2 | 2001 | 435 | |
| 3 | 2001 | 238 | |
| 4 | Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproductsbreakdown → | 1998 | 930 |
| 5 | 1996 | 247 |
About Luis Ferran
Luis Ferran is a scholar working on Clinical Biochemistry, Nephrology, Hematology, Rheumatology and Nutrition and Dietetics, having authored 5 papers that have together received 1.9k indexed citations. Recurring topics across this work include Advanced Glycation End Products research (3 papers), RNA Interference and Gene Delivery (1 paper), Natural Antidiabetic Agents Studies (1 paper), Diabetes, Cardiovascular Risks, and Lipoproteins (1 paper), T-cell and B-cell Immunology (1 paper), S100 Proteins and Annexins (1 paper), Immunotherapy and Immune Responses (1 paper) and Alzheimer's disease research and treatments (1 paper). The work is most often cited by research in Clinical Biochemistry (1.1k citations), Endocrinology, Diabetes and Metabolism (556 citations), Nephrology (203 citations), Rheumatology (317 citations) and Immunology (305 citations). Luis Ferran has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Ann Marie Schmidt, David M. Stern, Yan Lü, Wing Chow, Lisa Park, Kathleen G. Raman, Nozomu Tanji, M. Hofmann, Walter Kisiel and Evanthia Lalla. Their work appears in journals such as Journal of Clinical Investigation, Nature Medicine, Cancer Immunology Research and Arteriosclerosis Thrombosis and Vascular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.